Madrigal's Rezdiffra showed significant liver stiffness reduction in MASH cirrhosis. The company also beat Q4 earnings and revenue expectations.

We secured FDA approval for Rezdiffra, the first medicine approved for MASH, in March; executed a first-in-disease launch with remarkable results; and are well positioned for strong performance ...

By the end of last year, more than 11,800 patients were on Rezdiffra. In a conference call ... s consistent with other top tier specialty medicine launches,” Sibold added. On the prescriber ...

Madrigal Pharmaceuticals Inc (MDGL) reports robust financial performance with significant milestones in Rezdiffra's launch and market penetration.

Reports Q4 revenue $103.3M, consensus $97.81M. Bill Sibold, Chief Executive Officer of Madrigal, stated, “Looking back on 2024, I’m incredibly ...

Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with ...

Fred Craves, Ph.D. to retire from Madrigal’s Board of Directors in July 2025CONSHOHOCKEN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Madrigal ...

Our groundbreaking Rezdiffra Phase 3 trial data were published in the New England Journal of Medicine. On March 14, we achieved the milestone for the MASH field, the landmark approval of Rezdiffra ...

Our groundbreaking Rezdiffra, Phase 3 trial data were published in the New England Journal of Medicine. On March 14th, we achieved the milestone for the MASH field, the landmark approval of Rezdiffra, ...

and the early launch of Rezdiffra has demonstrated the compelling benefit that this innovative medicine represents for patients. I look forward to working with this team that has successfully ...